Gyre Therapeutics, Inc. Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
Gyre Therapeutics, Inc. (GYRE) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of -$14.27 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2026-08-07
- Gyre Therapeutics, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$14.27M.
- Gyre Therapeutics, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$9.86M, a 364.01% decline year-over-year.
- Gyre Therapeutics, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$1.37M, a 340.07% decline year-over-year.
- Gyre Therapeutics, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was $5.94M, a 107.84% increase year-over-year.
- Gyre Therapeutics, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2022 was $4.31M.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month as first filed | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month as first filed | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$14.27M 10-Q · filed 2026-08-07 | -$32.85M 10-Q · filed 2026-08-07 | -$25.49M derived: sum of 3 quarters · filed 2026-08-07 | -$19.56M derived: sum of 4 quarters · filed 2026-08-07 | ||
| 2026-03-31 | -$9.86M 10-Q · filed 2026-05-08 | -$11.22M derived: sum of 2 quarters · filed 2026-05-08 | -$5.29M derived: sum of 3 quarters · filed 2026-05-08 | -$7.53M derived: sum of 4 quarters · filed 2026-08-07 | ||
| 2025-12-31 | -$1.37M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-27 | $4.57M derived: sum of 2 quarters · filed 2026-04-27 | $2.33M derived: sum of 3 quarters · filed 2026-08-07 | $9.88M DEF 14A · filed 2026-04-27 | ||
| 2025-09-30 | $5.94M 10-Q · filed 2025-11-07 | $3.70M derived: sum of 2 quarters · filed 2026-08-07 | $11.25M 10-Q · filed 2025-11-07 | $8.00M derived: sum of 4 quarters · filed 2026-08-07 | ||
| 2025-06-30 | -$2.24M 10-Q · filed 2026-08-07 | $1.58M 10-Q · filed 2025-08-11 | $2.70M 10-Q · filed 2026-08-07 | $5.31M 10-Q · filed 2025-08-11 | $2.07M derived: sum of 3 quarters · filed 2026-08-07 | $4.92M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $3.73M 10-Q · filed 2026-05-08 | $4.30M derived: sum of 2 quarters · filed 2026-05-08 | $7.16M derived: sum of 3 quarters · filed 2026-05-08 | $11.70M derived: sum of 4 quarters · filed 2026-05-08 | ||
| 2024-12-31 | $569.00K derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-27 | $3.42M derived: sum of 2 quarters · filed 2026-04-27 | $7.96M derived: sum of 3 quarters · filed 2026-04-27 | $17.90M DEF 14A · filed 2026-04-27 | ||
| 2024-09-30 | $2.86M 10-Q · filed 2025-11-07 | $7.39M derived: sum of 2 quarters · filed 2025-11-07 | $17.33M 10-Q · filed 2025-11-07 | -$83.65M derived: sum of 4 quarters · filed 2026-04-27 | ||
| 2024-06-30 | $4.54M 10-Q · filed 2025-08-11 | $14.47M 10-Q · filed 2025-08-11 | -$86.50M derived: sum of 3 quarters · filed 2026-04-27 | -$78.99M derived: sum of 4 quarters · filed 2026-04-27 | ||
| 2024-03-31 | $9.94M 10-Q · filed 2025-05-09 | -$91.04M derived: sum of 2 quarters · filed 2026-04-27 | -$83.53M derived: sum of 3 quarters · filed 2026-04-27 | -$79.76M derived: sum of 4 quarters · filed 2026-04-27 | ||
| 2023-12-31 | -$100.98M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-27 | -$93.47M derived: sum of 2 quarters · filed 2026-04-27 | -$89.70M derived: sum of 3 quarters · filed 2026-04-27 | -$85.48M DEF 14A · filed 2026-04-27 | ||
| 2023-09-30 | $7.51M 10-Q · filed 2024-11-13 | $11.28M derived: sum of 2 quarters · filed 2024-11-13 | $15.50M 10-Q · filed 2024-11-13 | |||
| 2023-06-30 | $3.77M 10-Q · filed 2024-08-13 | $7.99M 10-Q · filed 2024-08-13 | ||||
| 2023-03-31 | $4.22M 10-Q · filed 2024-05-13 | |||||
| 2022-12-31 | $4.31M 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |